Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Penumbra (PEN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Recursion Pharmaceuticals (RXRX – Research Report) and Penumbra (PEN – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Recursion Pharmaceuticals (RXRX)
TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals today. The company’s shares closed last Wednesday at $3.88.
According to TipRanks.com, Smith is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Recursion Pharmaceuticals with a $7.75 average price target, which is a 98.2% upside from current levels. In a report released today, TipRanks – Google also downgraded the stock to Hold with a $3.50 price target.
See today’s best-performing stocks on TipRanks >>
Penumbra (PEN)
According to TipRanks.com, Kumar is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Penumbra with a $370.55 average price target.
